• Keine Ergebnisse gefunden

Table S2. Current pharmacotherapy of BD1 and BD2 groups.

N/A
N/A
Info
Herunterladen
Protected

Academic year: 2022

Aktie "Table S2. Current pharmacotherapy of BD1 and BD2 groups."

Copied!
2
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Jetzt herunterladen ( 2 Seite )

Volltext

(1)

Table S2. Current pharmacotherapy of BD1 and BD2 groups. Pharmacotherapy details are reported for each subject of both BD1 and BD2 groups.

ID Antipsychotic s

Lithiu m

Antiepileptic s

Antidepressant s

Anxiolyti c

Polypharmac y

BD1-1 X

BD1-2 X X X

BD1-3 X X X X

BD1-4 X X X X

BD1-5 X X X X

BD1-6 X

BD1-7 X X X

BD1-8 X X X X X

BD1-9 X X X

BD1-10 X X X X

BD1-11 X X X

BD1-12 X X X

BD1-13 X X X X

BD1-14 X X X X

BD1-15 X X X

BD1-16 X X X

(2)

BD1-17 X

BD2-1 X X X X

BD2-2 X X X X X

BD2-3 X X X

BD2-4 X

BD2-5 X

BD2-6 X X X X

BD2-7 X X X X

BD2-8 X

BD2-9 X X X X

BD2-10 X

BD2-11 X X X X

BD2-12 X

BD2-13 X X X

Referenzen

Jetzt herunterladen ( DOCX - 2 Seite - 19.39 KB )

ÄHNLICHE DOKUMENTE

Pharmacotherapy in the Management of Anxiety and Pain During Acute Coronary Syndromes and the Risk of Developing Symptoms of Posttraumatic Stress Disorder

ASD indicates acute stress disorder; CAPS, Clinician-Administered PTSD Scale; GRACE, Global Registry of Acute Coronary Events; IQR, interquartile range; MI, myocardial infarction;

Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German‑speaking countries

To conclude, our study found that psychiatric inpatients with a primary diagnosis of PTSD show high rates of psy- chotropic drug prescription in clinical routine, particularly of

Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes

However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

The present study was part of a larger pharmacovigilance project funded by the German Inno- vation Funds (OSA-PSY—Optimization of inpatient drug therapy for mental illnesses,

Imaging and pharmacotherapy of blood-brain barrier impairment during epileptogenesis

4.4.2 Longitudinal Magnetic Resonance imaging during epileptogenesis reveals blood-brain barrier leakage in epilepsy associated brain regions Longitudinal in vivo MRI was used

Table S2:

TI=(chorus frog* OR Pseudacris maculata OR boreal chorus frog OR Pseudacris triseriata OR Pseudacris crucifer) AND TI=(survival OR survivorship OR fertility OR demography OR

Table S2.

Phenotype (body mass index, body fat, leptin levels and metabolic abnormalities) in human mono- allelic likely pathogenic variants of the leptin gene (LEP wt/-) in comparison

Table S2

[r]